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Objective: Discrete morphologic, enzymatic and functional changes in skeletal muscle mitochondria have been demon-
strated in patients with peripheral arterial disease (PAD). We examined mitochondrial respiration in the gastrocnemius
muscle of nine patients (10 legs) with advanced PAD and in nine control patients (nine legs) without evidence of PAD.
Methods: Mitochondrial respiratory rates were determined with a Clark electrode in an oxygraph cell containing
saponin-skinned muscle bundles. Muscle samples were obtained from the anteromedial aspect of the gastrocnemius
muscle, at a level 10 cm distal to the tibial tuberosity. Mitochondria respiratory rate, calculated as nanoatoms of oxygen
consumed per minute per milligram of noncollagen protein, were measured at baseline (V0), after addition of substrates
(malate and glutamate; (VSUB), after addition of adenosine diphosphate (ADP) (VADP), and finally, after adenine
nucleotide translocase inhibition with atractyloside (VAT). The acceptor control ratio, a sensitive indicator of overall
mitochondrial function, was calculated as the ratio of the respiratory rate after the addition of ADP to the respiratory rate
after adenine nucleotide translocase inhibition with atractyloside (VADP/ VAT).
Results: Respiratory rate in muscle mitochondria from patients with PAD were not significantly different from control
values at baseline (0.31 0.06 vs 0.55 0.12; P .09), but Vsub was significantly lower in patients with PAD compared
with control subjects (0.43  0.07 vs 0.89  0.20; P < .05), as was VADP (0.69  0.13 vs 1.24  0.20; P < .05).
Respiratory rates after atractyloside inhibition in patients with PAD were no different from those in control patients
(0.47 0.07 vs 0.45 P .08). Compared with control values, mitochondria from patients with PAD had a significantly
lower acceptor control ratio (1.41  0.10 vs 2.90  0.20; P < .001).
Conclusion: Mitochondrial respiratory activity is abnormal in lower extremity skeletal muscle in patients with PAD. When
considered in concert with the ultrastructural and enzymatic abnormalities previously documented in mitochondria of
chronically ischemic muscle, these data support the concept of defective mitochondrial function as a pathophysiologic
component of PAD. (J Vasc Surg 2003;38:827-32.)
Insufficient oxygen supply secondary to reduced blood
flow is presumed to be the main physiologic cause for the
manifestations of peripheral arterial disease (PAD). More
recently, however, a number of investigators have proposed
the presence of mitochondriopathy in chronically ischemic
skeletal muscle.1-10 Their findings suggest that in addition
to reduced oxygen supply, suboptimal energy production
from defective mitochondria may be a factor in PAD patho-
genesis.
Over the last decade a number of studies have docu-
mented that mitochondria in chronically ischemic muscle
have abnormal ultrastructure,1 damaged DNA,2 altered
enzyme expression and activity, and abnormally high inter-
mediates of oxidative metabolism.3,4 In these studies mito-
chondria were evaluated in fixed or frozen muscle samples,
which precluded simultaneous study of mitochondrial re-
spiratory function. As a result, it is difficult to draw any
definitive conclusions about the functional significance of
these findings. Our laboratory and others have used phos-
phorus 31 magnetic resonance spectroscopy (31P MRS)6-10
to study the bioenergetics of chronically ischemic skeletal
muscle during various types of exercise. These in vivo
studies of mitochondrial function demonstrate an intrinsic
defect in mitochondrial respiration, similar to that in the
mitochondrial myopathies.5,11 The main limitation of 31P
MRS is that the extramitochondrial milieu cannot be mea-
sured or controlled. In addition, unless the exercise proto-
col is carefully designed and regulated, it can introduce the
confounding influence of blood flow differences (at rest
and with exercise) on bioenergetics, making data interpre-
tation a challenge.
To further define and characterize the functional defect
in mitochondria in PAD, we performed an in vitro evalua-
tion of mitochondrial respiration in freshly harvested and
processed skeletal muscle samples. Specimens were treated
with mechanical dissection and chemical permeabilization
to obtain skinned muscle fibers. The mitochondrial respi-
ratory function of these fibers was then evaluated in vitro
with polarography. This processing removes the sarcolem-
mal membrane and the cytosol, but preserves the ultra-
structure of mitochondria and other intracellular or-
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ganelles. The total mitochondrial population is accessible
with this technique, thereby enabling direct investigation
of mitochondrial respiratory function with complete con-
trol of the mitochondrial milieu.12-15
We studied patients with more advanced PAD than
have been studied previously, focusing on patients with
severe claudication and critical limb ischemia in need of
either revascularization or amputation. Patients with ad-
vanced lower extremity PAD usually have very short dis-
tance claudication (muscle pain with minimal amount of
exercise, which is relieved by rest) or critical limb ischemia
(rest pain and tissue loss, usually involving the foot and
toes). These patients have indications for either revascular-
ization or, in the most severe cases, amputation to control
complications of ischemia. Defective muscle cell bioener-
getics may contribute to muscle dysfunction of claudication
and the production of rest pain and tissue loss or gangrene
in the severely ischemic limb.
METHODS
The experimental protocol and consent form were
approved by the institutional review board, and all subjects
gave informed consent.
Study group. We recruited nine patients (10 legs)
undergoing lower extremity operations because of ad-
vanced ischemia (life-style limiting claudication, rest pain,
or tissue loss) (Table I). Patient mean age was 65 years.
Each patient had, on average, 2.5 risk factors for athero-
sclerosis. Risk factors included diabetes, hypertension,
smoking, dyslipidemia, coronary artery disease, obesity,
and family history of complications of atherosclerotic dis-
ease. Six patients (six legs) underwent femoropopliteal or
femorotibial bypass grafting, and in the other three patients
(four legs) a major amputation procedure was performed.
The diagnosis of PAD was objectively established on the
basis of a combination of history, positive findings at phys-
ical examination, and significantly decreased ankle-brachial
index (ABI; mean, 0.4) or toe pressure. In addition, angio-
graphic documentation of PAD was available for seven of
the nine patients. The diagnostic workup revealed evidence
of femoropopliteal occlusive disease in five patients (five
legs), and combined femoropopliteal and crural occlusive
disease in the other four patients (five legs).
Control group. Nine patients (nine legs) undergoing
lower extremity operations because of indications other
than PAD were recruited. Patient mean age was 47 years.
Each patient had, on average, one risk factor for atheroscle-
rosis. Six patients had lower extremity venous disease, two
patients had lower extremity orthopedic problems, and one
patient had lower extremity trauma. These patients had no
history of PAD symptoms, and all had normal lower ex-
tremity pulse at examination and noninvasive testing (ABI
1.0 at rest and after exercise). All control patients had a
sedentary lifestyle.
Biopsy technique. Muscle biopsy samples were ob-
tained from the gastrocnemius muscle, exposed through
the incision made for the primary procedure. All muscle
samples were obtained from the anteromedial aspect of the
gastrocnemius muscle belly, at a level 10 cm distal to the
tibial tuberosity. Identical operative technique was used for
muscle harvest in all patients.
Tissue preparation for mitochondrial respiration
measurement.12 After a brief rinse in ice-cold Ringer so-
lution, the tissue specimen was transferred to ice-cold re-
laxing solution A, and minced with sharp forceps into
bundles approximately 0.3 to 0.4 mm in diameter. Relax-
ing solution A consisted of 10 mmol/L of ethylene glycol
tetraacetic acid (EGTA), 3 mmol/L of free Mg, 20
mmol/L of taurine, 0.5 mmol/L of dithiothreitol, 20
mmol/L of imidazole, 0.16 mol/L of potassium 4-mor-
pholine ethanesulfonate (pH, 7.2), 5 mmol/L of adenosi-
notriphosphate (ATP) magnesium salt, and 15 mmol/L of
phosphocreatine sodium salt. To remove intracellular cal-
cium, the muscle bundles were softly agitated for 2 hours in
relaxing solution A. Bundles were then skinned in relaxing
solution A containing 100 g/mL of saponin. Saponin is a
glycoside of plant origin that in very low concentrations
selectively removes the sarcolemma (myocyte membrace)
without any visible effect on mitochondria or other intra-
cellular structures. Saponin selectivity for sarcolemma lies in
its hydrophobic core, which has high affinity for choles-
terol. Sarcolemma is rich in cholesterol, whereas the mem-
branes of mitochondria and endoplasmic reticulum contain
little cholesterol.13 The 20-minute skinning procedure was
performed while the sample was being vigorously stirred at
4°C. After skinning, specimens were washed for 30 minutes
in solution B to remove saponin and to reduce intracellular
concentrations of high-energy phosphates and nicotine
adenine nucleotide–dependent substrates. Solution B con-
sisted of 10 mmol/L of EGTA, 3 mmol/L of free Mg,
20 mmol/L of taurine, 0.5 mmol/L of dithiothreitol, 20
mmol/L of imidazole, 0.16 mol/L of potassium 4-mor-
pholine ethane sulfonate (pH, 7.2), 3 mmol/L of phos-
phate, and 10 mg/mL of fatty acid–free bovine serum
albumin. Specimens were washed again for 30 minutes in
fresh solution B before being placed in the oxygraph cham-
ber for determination of mitochondrial respiration.
The mitochondrial yield and quality in the skinned fiber
preparation has been extensively investigated by our team
and others. Transmission and scanning electron micros-
copy of skinned muscle bundles demonstrate complete
removal of the sarcolemma, with preservation of the total
number of mitochondria.12,14-19 In addition, embedment-
free electron microscopy demonstrates that these mito-
chondria are morphologically intact and maintain undam-
aged contacts with the cytoskeleton and other subcellular
organelles.20 Furthermore, biochemical evaluation of
skinned muscle bundles demonstrates no solute barriers
between the intracellular and extracellular spaces, enabling
complete control of mitochondrial physiology with the
addition of external components.12,16,18 Most important,
the mitochondrial respiration in skinned muscle fibers is
functionally comparable to that of high-quality isolated
mitochondria preparations.12,21,22
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Measurement of mitochondrial respiratory
rates. Mitochondrial respiratory rates were determined
with a Clark electrode (Yellow Springs Instruments, Yellow
Springs, Ohio) in an oxygraph cell containing 15 to 20
muscle bundles in 3 mL of solution B at 34°C, with
continuous stirring. The solubility of oxygen at 34°C was
taken to be 386 natoms/mL. Respiratory parameters mea-
sured included basal respiratory rate (V0), respiratory rate
after addition of substrates (0.7 mmol/L of malate, 1.7
mmol/L of glutamate; (VSUB), respiratory rate after fur-
ther addition of 1 mmol/L of ADP (VADP), and respiratory
rate after addition of 0.35 mmol/L of atractyloside (VAT).
Atractyloside is an inhibitor of the adenosine triphosphate
(ATP)–ADP translocase, a mitochondrial membrane pro-
tein that exports ATP to the cytosol in exchange for ADP,
which is used in the mitochondria to manufacture addi-
tional ATP. Inhibition of ATP-ADP translocase halts entry
of ADP into the mitochondria, enabling testing of their
respiratory function in the absence of ADP.
The most important components of this investigation
are VADP, and VAT. VADP represents a state of maximal
mitochondrial stimulation, or state 3 respiration, whereas
VAT represents a state of maximal inhibition, or atractylo-
side-sensitive oxidative phosphorylation. Measurements
obtained at baseline and after substrate addition alone have
little or no significance to the overall evaluation. Specifi-
cally, at baseline the processed muscle fibers have no cy-
tosol, and therefore minimal residual substrate and ADP.
The similarity of respiratory rates at baseline reflects that
specimen preparation in both groups removed the cytosol
and most of the substrates and ADP within it. The acceptor
control ratio, a sensitive indicator of mitochondrial func-
tion, was calculated as the ratio of state 3 respiration (VADP)
to respiratory rate after ATP-ADP translocase inhibition
(VAT) with atractyloside (VADP/VAT). This ratio is a sensi-
tive indicator of overall mitochondrial function, and repre-
sents the relative difference between the two extremes of
mitochondrial function that occur in the presence and
absence of ADP.
After completion of all measurements, tissue was pro-
cessed for determination of the amount of non-collagen
protein, with the method of Lowry et al.23 Respiratory rate
was expressed as nanoatoms of oxygen consumed per
minute per milligram of non-collagen protein. For quality
control, mitochondrial respiratory rates were measured on
each study day in myocardial specimens obtained from
normal Swiss Webster mice. A 30% to 50% increase in
mitochondrial state 3 respiration beyond that achieved after
addition of substrates was considered a normal response
and confirmation of proper assay and equipment perfor-
mance.
Statistical analysis. Descriptive statistics were com-
puted for the variables of interest in the two groups. To test
for differences between control and PAD groups in respi-
ratory rate at different stages of the polarography experi-
ment and in the acceptor control ratios, a t statistic for two
means was used. For this test, P  .05 was considered
significant. Data are reported as mean  SEM.
RESULTS
Chronically ischemic mitochondria from patients with
PAD demonstrated similar respiratory rate at baseline,
compared with that in control patients. VSUB was signifi-
cantly lower in patients with PAD compared with control
patients. Similarly, VADP remained significantly lower in
patients with PAD than in control patients. VAT in patients
with PAD was similar to that in control patients. Mitochon-
dria from patients with PAD, compared with control pa-
tients, had a significantly lower acceptor control ratio (Ta-
ble II; Figure).
No attempt was made to correlate level of mitochon-
drial function with clinical manifestations of PAD in our
study patients. It was thought that such a correlation would
not be fruitful, because the group was small and homoge-
neous, containing only patients with very advanced disease
(two patients with very short distance claudication and
seven with rest pain or tissue loss). In such a group, differ-
ences in clinical manifestations are too small to be corre-
lated, even with results obtained at conventional noninva-
sive testing and arteriography.
DISCUSSION
Mitochondria in chronically ischemic muscle have ab-
normal ultrastructure,1 extensively damaged DNA,2 al-
tered expression and activities of enzymes, and abnormally
high intermediates of oxidative metabolism.3,4 More re-
markable, an intrinsic defect in mitochondrial function
similar to that in mitochondrial myopathies5 has been
demonstrated by our team and others when the bioener-
getics of chronically ischemic skeletal muscle was studied
with 31P MRS.6-10 When legs with different levels of isch-
emia were evaluated with 31P MRS, it was found that
extremities with severe ischemia had the most defective
oxidative function.9 Analysis of 31P MRS findings6 suggests
that a combination of factors related to intensity and fre-
quency of “ischemic insult,” and possibly the ischemia-
reperfusion associated with it, may be responsible for
defective mitochondria.
Revascularization of a chronically ischemic limb does
not reverse mitochondrial oxidative dysfunction until sev-
eral months after the intervention.9 In addition, revascular-
ization does not normalize exercise performance in the leg
with claudication.24 However, treatment with pentoxifyl-
line (first drug approved by the US Food and Drug Admin-
istration for treatment of claudication) in a selected group
of patients with moderate claudication improved leg exer-
cise performance in a fashion directly proportional to im-
provement in muscle mitochondrial function.7 These stud-
ies suggest that impaired arterial perfusion may not be the
only factor that determines leg function in PAD. Treatment
of mitochondriopathy in chronically ischemic skeletal mus-
cle may be an independent therapeutic method capable of
producing significant functional improvement with or
without concomitant revascularization.11,25
We attempted to further evaluate the function of mito-
chondria in chronically ischemic muscle. Maximal mito-
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chondrial respiratory rate (VADP) after stimulation of the
electron transport chain with the electron donor substrates
malate and glutamate in the presence of ADP (final electron
acceptor in oxidative phosphorylation) was significantly
higher in control mitochondria than in PAD mitochondria.
When respiration was inhibited by depriving the mitochon-
dria of ADP, after atractyloside inhibition of ATP-ADP
translocase, the rate returned to similar levels in both
ischemic and control muscle. This difference between the
two extremes in mitochondrial function was reflected in a
significantly lower acceptor control ratio in mitochondria
from patients with PAD compared with control patients.
Both diminished response to stimulation with substrates
and ADP, and lower acceptor control ratio, document
significant mitochondrial dysfunction in chronically isch-
emic skeletal muscle.
Mitochondrial dysfunction may have two major nega-
tive consequences. First, PAD mitochondria do not have
the capacity to produce as much ATP as normal skeletal
muscle mitochondria do. Patients with PAD are thus in
double jeopardy; not only do they have a decreased supply
of nutrients and oxygen, as a result of diseased arteries, but
the concurrent mitochondrial respiratory defect leads to
even less ATP production with the limited supplies of
oxygen and nutrients present. Second, dysfunctional mito-
chondria are a source of abnormally high levels of reactive
oxygen species, which may be independently injurious to
the mechanisms that sustain normal cellular structure and
function. The end result of this process is a significant
decrease in energy production and a potentially increased
level of destructive oxygen radicals in the skeletal myocytes
of patients with PAD.26
Table I. Demographic data for patients with PAD
Patient Age (y) Gender Presentation ABI
Extent of
PAD Operation Risk factors VADP
1 51 Female Tissue loss 0.3 FP Revascularization 3 1.10
2 76 Female Calf claudication 0.4 FP Revascularization 2 1.17
3 65 Male Tissue loss 0.5 FP Revascularization 3 0.61
4 62 Male Tissue loss 0.3 FP  crural Amputation 3 1.33
5 Left leg 75 Female Tissue loss IC FP  crural Amputation 3 0.57
5 Right leg Female Tissue loss IC FP  crural Amputation 3 0.86
6 63 Male Tissue loss 0.6 FP Revascularization 1 0.40
7 67 Female Rest pain 0.4 FP  crural Revascularization 3 0.23
8 87 Female Tissue loss 0.3 FP  crural Amputation 2 0.40
9 42 Female Calf claudication 0.5 FP Revascularization 3 0.25
PAD, Peripheral arterial disease; ABI, ankle brachial index; IC, incompressible; FP, femoropopliteal segment; VADP, respiratory rate in presence of substrates
(malate and glutamate) and adenosine diphosphate.
Comparison of gastrocnemius muscle respiratory rate in patients with peripheral arterial disease (PAD) and control patients. Baseline,
Respiratory rate at baseline; Substrate, respiratory rate after addition of malate and glutamate; ADP, respiratory rate after further addition
of adenosine diphosphate; Atractyloside, respiratory rate after adenine nucleotide translocase inhibition with atractyloside. P  .05.
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It is important to point out that this study was designed
to demonstrate the association between PAD and dysfunc-
tional skeletal muscle mitochondria. A cause-and-effect
relationship between the two cannot be established on the
basis of these data. Additional work, with an animal model
of hind limb ischemia, is currently under way in our labo-
ratory, to clarify whether atherosclerosis specifically or isch-
emia alone from other disease is the cause of this dysfunc-
tion.
The skinned fiber technique is the ideal tool for assess-
ment of mitochondrial respiratory efficiency when the sam-
ple is small (in our study, wet weight was 50-100 mg), as is
usually the case in clinical studies in human subjects. A
limitation of this technique is that the results are normal-
ized to non-collagen protein and not to citrate synthase
activity. The denominator of choice would have been ci-
trate synthase activity, which is more specific than non-
collagen protein for amount of mitochondria in a muscle
sample. However, measurement of citrate synthase levels
requires a substantially larger volume of muscle tissue than
was available in this clinical study. More important, work
from several laboratories has identified increased mitochon-
dria content, reflected in increased citrate synthase levels
per unit of non-collagen protein, in the muscle of patients
with PAD compared with control subjects.27-30 Therefore,
if anything, use of citrate synthase for calculation of respi-
ratory rate would have further increased the differences
demonstrated between PAD muscle and control muscle,
making them even more significant.
Another potential limitation of our study is that mean
age of our patients with PAD was 65 years, compared with
47 years in the control group. This age difference could be
important if mitochondrial function declines with age.
However, the available data in human subjects show no
age-related difference in malate-based VADP in patients
with age range 40 to 90 years.31,32 Similarly, when mito-
chondrial function was extensively tested in an animal
model of aging, no differences in malate-based VADP rates
could be demonstrated between adult and older animals.33
Therefore it is unlikely that the mitochondrial dysfunction
in our PAD muscle specimens is secondary to the age
difference between the PAD and control groups.
In conclusion, our results demonstrate defective mito-
chondrial respiratory activity in chronically ischemic gas-
trocnemius muscle. Although the mechanisms responsible
for this mitochondrial respiratory defect are not fully un-
derstood, our observations suggest that impaired efficiency
of one or more components of the electron transport chain
and oxidative phosphorylation may be the central underly-
ing mechanism. A better understanding of these mecha-
nisms may enable development of improved therapy for
PAD through prevention or treatment of mitochondrial
disease. Such therapy has the potential to produce signifi-
cant improvement in PAD-related morbidity and mortality.
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